Abstract

Bacterial capsules are common targets for antibody-mediated immunity. The capsule of Bacillus anthracis is unusual among capsules because it is composed of a polymer of poly-γ-d-glutamic acid (γdPGA). We previously generated murine IgG3 monoclonal antibodies (mAbs) to γdPGA that were protective in a murine model of pulmonary anthrax. IgG3 antibodies are characteristic of the murine response to polysaccharide antigens. The goal of the present study was to produce subclass switch variants of the γdPGA mAbs (IgG3→IgG1→IgG2b→IgG2a) and assess the contribution of subclass to antibody affinity and protection. Subclass switch antibodies had identical variable regions but differed in their heavy chains. The results showed that a switch from the protective IgG3 to IgG1, IgG2b or IgG2a was accompanied by i) a loss of protective activity ii) a change in mAb binding to the capsular matrix, and iii) a loss of affinity. These results identify a role for the heavy chain constant region in mAb binding. Hybrid mAbs were constructed in which the CH1, CH2 or CH3 heavy chain constant domains from a non-protective, low binding IgG2b mAb were swapped into the protective IgG3 mAb. The IgG3 mAb that contained the CH1 domain from IgG2b showed no loss of affinity or protection. In contrast, swapping the CH2 or CH3 domains from IgG2b into IgG3 produced a reduction in affinity and a loss of protection. These studies identify a role for the constant region of IgG heavy chains in affinity and protection against an encapsulated bacterial pathogen.

Highlights

  • Bacillus anthracis, the causative agent of anthrax, is a grampositive, spore-forming bacterium [1]

  • We examined binding of antibodies to an outer coat of the biothreat Bacillus anthracis that is essential for bacterial virulence

  • The results of the study have implications for i) understanding how antibodies function in protection against anthrax and possibly other diseases, ii) understanding how the host responds to a key bacterial virulence factor, iii) selection of antibodies that might be used to treat anthrax, and iv) design of vaccines to protect against anthrax

Read more

Summary

Introduction

The causative agent of anthrax, is a grampositive, spore-forming bacterium [1]. Virulent strains of B. anthracis carry two large plasmids, pXO1 and pXO2, that encode genes needed for toxin production and capsule formation, respectively [2,3]. Anthrax toxins are composed of protective antigen (PA) combined with lethal factor (LF) or edema factor (EF) to form active toxins [4,5]. The current vaccine, anthrax vaccine adsorbed (AVA, Biothrax), is composed of aluminum hydroxide-adsorbed, formalintreated, cell-free filtrate of a non-capsulated B. anthracis strain [10]. CDPGA-based immunity is attractive because such immunity would interdict the infection when the bacterial load is low and would prevent infection from reaching the stage where large amounts of toxin are formed. CDPGAspecific antibodies could exhibit potent synergy with toxin-targeted immunity [11]

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call